| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 890 | 2014 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 631* | 2019 |
| International prognostic scoring system for Waldenström macroglobulinemia P Morel, A Duhamel, P Gobbi, MA Dimopoulos, MV Dhodapkar, J McCoy, ... Blood, The Journal of the American Society of Hematology 113 (18), 4163-4170, 2009 | 454 | 2009 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 439 | 2016 |
| International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ... The lancet oncology 20 (6), e302-e312, 2019 | 381 | 2019 |
| The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes S Tabera, JA Pérez-Simón, M Díez-Campelo, LI Sánchez-Abarca, ... haematologica 93 (9), 1301-1309, 2008 | 370 | 2008 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 325 | 2017 |
| New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, ... Leukemia 28 (3), 525-542, 2014 | 306 | 2014 |
| The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance P Maiso, X Carvajal-Vergara, EM Ocio, R López-Pérez, G Mateo, ... Cancer research 66 (11), 5781-5789, 2006 | 305 | 2006 |
| MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia C Jiménez, E Sebastián, MC Chillón, P Giraldo, J Mariano Hernández, ... Leukemia 27 (8), 1722-1728, 2013 | 302 | 2013 |
| Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop RG Owen, RA Kyle, MJ Stone, AC Rawstron, V Leblond, G Merlini, ... British journal of haematology 160 (2), 171-176, 2013 | 293 | 2013 |
| Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel J Caers, B Paiva, E Zamagni, X Leleu, J Bladé, SY Kristinsson, ... Journal of hematology & oncology 11, 1-10, 2018 | 263 | 2018 |
| Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia MA Dimopoulos, MA Gertz, E Kastritis, R Garcia-Sanz, EK Kimby, ... J Clin Oncol 27 (1), 120-126, 2009 | 255 | 2009 |
| Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic … NC Gutierrez, EM Ocio, J de Las Rivas, P Maiso, M Delgado, E Ferminan, ... Leukemia 21 (3), 541-549, 2007 | 222 | 2007 |
| Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, ... The Lancet Haematology 6 (9), e459-e469, 2019 | 220 | 2019 |
| Immunophenotypic analysis of Waldenstrom's macroglobulinemia JF San Miguel, MB Vidriales, E Ocio, G Mateo, F Sanchez-Guijo, ... Seminars in oncology 30 (2), 187-195, 2003 | 210 | 2003 |
| 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and … T Kiziltepe, T Hideshima, L Catley, N Raje, H Yasui, N Shiraishi, Y Okawa, ... Molecular cancer therapeutics 6 (6), 1718-1727, 2007 | 200 | 2007 |
| PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma B Paiva, A Azpilikueta, N Puig, EM Ocio, R Sharma, BO Oyajobi, ... Leukemia 29 (10), 2110-2113, 2015 | 199 | 2015 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 198 | 2021 |
| Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia SP Treon, MA Gertz, M Dimopoulos, A Anagnostopoulos, J Blade, ... Blood 107 (9), 3442-3446, 2006 | 196 | 2006 |
